GALDZ.XC
Galderma Group AG
Cboe UKCHFEQUITY
Healthcare
DELAYED
Last price
171.00
▼ 0.50 (0.29%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
171.50
Day high
172.15
Day low
170.00
Volume
39.98K
Market cap
$40.11B
P/E (TTM)
58.56
52W range
130.10 – 188.30
Trailing performance
Returnvs SPY
1W
-0.88%
+0.3%
1M
+1.15%
-2.2%
3M
+8.17%
+5.8%
6M
+11.08%
-0.8%
YTD
+5.60%
-6.4%
1Y
+26.38%
+6.3%
3Y
—
-75.0%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on GALDZ.XC open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
49.02M
Total on file
Fundamentals
Market cap$40.11B
Enterprise value$41.75B
Revenue (TTM)$5.92B
Gross profit$4.11B
EBITDA$1.39B
Net income$863.00M
EPS (TTM)$2.92
Free cash flow$874.63M
Total cash$839.00M
Total debt$2.72B
Book value / share$28.56
Shares outstanding234.57M
Float131.27M
Short % of float—
Dividend yield0.20%
Beta (5Y)-0.10
Valuation & profitability ratios
Trailing P/E58.56
Forward P/E—
PEG ratio1.74
Price / sales—
Price / book5.99
EV / revenue7.05
EV / EBITDA30.12
Gross margin69.37%
Operating margin20.23%
Profit margin14.57%
Return on equity10.82%
Return on assets5.36%
Debt / equity33.06
Current ratio1.24
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $5.24B | $4.44B | $4.12B | $3.82B | +18.0% |
| Operating revenue | $5.24B | $4.44B | $4.12B | $3.82B | +18.0% |
| Cost of revenue | $1.63B | $1.35B | $1.23B | $1.19B | +20.4% |
| Gross profit | $3.61B | $3.08B | $2.88B | $2.63B | +17.0% |
| Research & development | $245.00M | $260.00M | $287.00M | $315.90M | -5.8% |
| Selling, general & admin | $2.37B | $2.05B | $1.89B | $1.82B | +15.6% |
| Total operating expense | $2.73B | $2.41B | $2.27B | $2.22B | +13.5% |
| Operating income | $876.00M | $678.00M | $611.00M | $406.00M | +29.2% |
| Net interest income | -$178.00M | -$334.00M | -$526.00M | -$385.40M | +46.7% |
| Pre-tax income | $638.00M | $310.00M | $11.00M | -$51.90M | +105.8% |
| Tax provision | $26.00M | $79.00M | $68.00M | $45.00M | -67.1% |
| Net income | $613.00M | $231.00M | -$57.00M | -$98.50M | +165.4% |
| Net income to common | $613.00M | $231.00M | -$57.00M | -$98.50M | +165.4% |
| Basic EPS | 2.60 | 0.97 | -0.24 | -0.41 | +168.0% |
| Diluted EPS | 2.58 | 0.97 | -0.24 | -0.41 | +166.0% |
| EBIT | $813.00M | $666.00M | $575.00M | $346.50M | +22.1% |
| EBITDA | $1.14B | $959.00M | $851.00M | $624.20M | +18.5% |
| Basic shares | 235.72M | 237.52M | 237.57M | 237.57M | -0.8% |
| Diluted shares | 237.00M | 237.79M | 237.57M | 237.57M | -0.3% |
| Line item | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|
| Cash & equivalents | $780.00M | $457.00M | $368.00M | +70.7% |
| Cash & short-term investments | $780.00M | $457.00M | $368.00M | +70.7% |
| Accounts receivable | $893.00M | $754.00M | $631.00M | +18.4% |
| Inventory | $525.00M | $403.00M | $420.00M | +30.3% |
| Total current assets | $2.44B | $1.84B | $1.62B | +32.2% |
| Property, plant & equipment | $744.00M | $578.00M | $530.00M | +28.7% |
| Goodwill & intangibles | $9.77B | $9.96B | $10.05B | -1.9% |
| Total assets | $13.39B | $12.62B | $12.47B | +6.2% |
| Total current liabilities | $2.06B | $1.53B | $1.57B | +34.5% |
| Current debt | $27.00M | $6.00M | $39.00M | +350.0% |
| Long-term debt | $2.58B | $2.64B | $4.75B | -2.2% |
| Total debt | $2.75B | $2.76B | $4.91B | -0.2% |
| Total liabilities | $5.24B | $4.83B | $7.10B | +8.6% |
| Retained earnings | $6.35B | $5.68B | -$901.00M | +11.8% |
| Shareholder equity | $8.15B | $7.79B | $5.37B | +4.6% |
| Working capital | $382.00M | $315.00M | $45.00M | +21.3% |
| Net tangible assets | -$1.62B | -$2.17B | -$4.68B | +25.3% |
| Shares issued | 237.90M | 237.90M | 237.57M | 0.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $613.00M | $231.00M | -$57.00M | -$98.50M | +165.4% |
| Depreciation & amortisation | $323.00M | $293.00M | $276.00M | $277.70M | +10.2% |
| Stock-based compensation | $64.00M | $68.00M | $0 | — | -5.9% |
| Change in working capital | $194.00M | -$148.00M | -$35.00M | -$78.50M | +231.1% |
| Operating cash flow | $1.19B | $488.00M | $165.00M | $111.30M | +142.8% |
| Capital expenditure | -$154.00M | -$275.00M | -$153.00M | -$159.50M | +44.0% |
| Investing cash flow | -$154.00M | -$326.00M | -$174.00M | -$66.50M | +52.8% |
| Share buybacks | -$363.00M | -$15.00M | $0 | — | -2,320.0% |
| Dividends paid | -$41.00M | — | — | — | — |
| Financing cash flow | -$728.00M | -$58.00M | $142.00M | -$79.40M | -1,155.2% |
| Free cash flow | $1.03B | $213.00M | $12.00M | -$48.20M | +384.0% |
| End cash position | $780.00M | $457.00M | $368.00M | $234.10M | +70.7% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
| Line item | 2025-12-31 | 2025-06-30 | 2024-12-31 | YoY |
|---|---|---|---|---|
| Cash & equivalents | $780.00M | $458.00M | $457.00M | +70.3% |
| Cash & short-term investments | $780.00M | $458.00M | $457.00M | +70.3% |
| Accounts receivable | $893.00M | $857.00M | $754.00M | +4.2% |
| Inventory | $525.00M | $502.00M | $403.00M | +4.6% |
| Total current assets | $2.44B | $1.91B | $1.84B | +27.6% |
| Property, plant & equipment | $744.00M | $672.00M | $578.00M | +10.7% |
| Goodwill & intangibles | $9.77B | $9.88B | $9.96B | -1.1% |
| Total assets | $13.39B | $12.88B | $12.62B | +4.0% |
| Total current liabilities | $2.06B | $1.75B | $1.53B | +17.4% |
| Current debt | $27.00M | $20.00M | $6.00M | +35.0% |
| Long-term debt | $2.58B | $2.70B | $2.64B | -4.4% |
| Total debt | $2.75B | $2.85B | $2.76B | -3.3% |
| Total liabilities | $5.24B | $5.15B | $4.83B | +1.9% |
| Retained earnings | $6.35B | $5.90B | $5.68B | +7.6% |
| Shareholder equity | $8.15B | $7.73B | $7.79B | +5.4% |
| Working capital | $382.00M | $160.00M | $315.00M | +138.8% |
| Net tangible assets | -$1.62B | -$2.15B | -$2.17B | +24.7% |
| Shares issued | 237.90M | 237.90M | 237.90M | 0.0% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $1.57B | +22.2% |
| Next quarter | — | — | $1.67B | +13.8% |
| Current year | — | — | $6.41B | +23.0% |
| Next year | — | — | $7.49B | +18.3% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders21.02%
Held by institutions48.22%
Institutions holding520
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
172.86
-1.07% from price
SMA 20
175.04
-2.02% from price
SMA 50
174.94
-1.96% from price
SMA 100
167.65
+2.00% from price
SMA 200
160.53
+6.84% from price
EMA 12
172.79
-1.04% from price
EMA 26
173.73
-1.57% from price
EMA 50
172.56
-0.90% from price
RSI (14)
46.6
Neutral
MACD (12,26,9)
-0.94
Hist -0.85
ATR (14)
4.84
2.82% of price
Realised vol 30D
27.5%
Annualised
Bollinger upper
182.35
20, 2σ
Bollinger lower
167.72
20, 2σ
50 / 200 cross
Golden
174.94 vs 160.53
Trend bias
Above 200
+6.84%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.08
Less volatile than market
Correlation to SPY
0.04
Largely independent
Realised vol 30D
27.5%
Annualised
Market vol 1Y
12.8%
SPY, annualised
Max drawdown 1Y
-15.4%
Peak to trough
Max drawdown 5Y
-38.0%
Peak to trough
ATR 14
4.84
2.82% of price
Beta (reported)
-0.10
5Y monthly, from filing
Dividends & splits
Forward rate$0.35 / yr
Forward yield0.20%
5-year avg yield—
Payout ratio12.12%
Ex-dividend dateApr 24, 2026
Next pay date—
Last split—
Split date—
Headlines
Net Asset Value(s)
Business Wire · 6m ago
AstraZeneca prices €2.55bn euro bond sale across four tranches
Proactive · 7m ago
Trees 'giving up': climate change hammers historic English gardens
AFP · 10m ago
Implantica to host Capital Markets Day in Stockholm on September 9
PR Newswire · 10m ago
Saudi Arabia to fund three new theme parks near Paris
Euronews · 11m ago
Cadeler: Q2 Earnings Snapshot
Associated Press · 12m ago
Solvonis raises £1.3m to fund three clinical programmes
Proactive · 12m ago
ZINZINO AB (PUBL.): INTERIM REPORT Q2 2026
PR Newswire · 13m ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.